Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Ameron International Corporation (NYSE: AMN) and Watsco, Incorporated (NYSE: WSO). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Amedisys, Inc. (Nasdaq: AMED).
To see the full Zacks #5 Rank List – Stocks to Sell Now visit: http://at.zacks.com/?id=92
Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.
Here is a synopsis of why AMN and WSO have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:
Ameron International Corporation (NYSE: AMN) announced second-quarter profit of 11 cents per share on July 8 that missed analysts’ expectations by 81.7%. The Zacks Consensus Estimate for the current year slipped to $1.40 per share from $1.95 per share in the last 30 days as next year’s estimate dipped 9 cents per share to $3.45 per share in that time span.
Watsco, Incorporated (NYSE: WSO) posted a second-quarter profit of $1.09 per share on July 26, which came in 21 cents wider than the average forecast. The Zacks Consensus Estimate for the full year fell to $2.91 per share from $3.20 per share over the past month. For 2012, analysts expect a profit of $3.59 per share, compared to last month’s projection for a profit of $3.96 per share.
Here is a synopsis of why REGN and AMED have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) second-quarter loss of 69 cents per share, posted on July 28, lagged analysts’ projections by 68.29%. Estimate for current year slid 45 cent per share to a loss of $2.33 per share over the past month as next year’s estimate dipped 35 cents per share to a loss of $1.30 per share in that time span.
Amedisys, Inc. (Nasdaq: AMED) reported a second-quarter profit of 67 cents per share on August 2 that fell 2.90% short of the Zacks Consensus Estimate. The full-year average forecast is currently $2.30 per share, compared with last month’s projection of $3 per share. Next year’s forecast dropped to $2.93 per share from $3.09 per share in the same period.
Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; “Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions” is available to provide this insightful background. Download a free copy now to prosper in the years to come at http://at.zacks.com/?id=93
About the Zacks Rank
Since 1988, the Zacks Rank has proven that “Earnings estimate revisions are the most powerful force impacting stock prices.” Since inception in 1988, #1 Rank Stocks have generated an average annual return of +28%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (2.8% versus +9.7%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks “Profit from the Pros” e-mail newsletter offers continuous coverage of Zacks Rank Buy stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=94
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=95
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
Tagged with: (NASDAQ: AMED) • (NASDAQ: REGN) • (NYSE: AMN) • (NYSE: WSO) • 401(k) • Asset Management • Bond Fund • Bond Funds • Bond Market • Business • Capital market • CBOE • CEO • CFO • CME • Common stock • Dividends • DJIA • Doctor of Philosophy • etf • ETF Fund • Financial planner • Financial Services • FX Market • Index fund • Industry • Inflation • Interest Rates • IPO • Markets • Mergers & Acqusitions • Mutual Funds • NASDAQ • New York Stock Exchange • NYSE • OTC • Preferred stock • Profit (accounting) • Regeneron • ROI • S&P • SEC • Stock market • Stock Offering • Technology • Venture capital • Wall Street • Watsco • Zacks
Filed under: Business